Men with a History of Testicular Cancer

Article

Risk of developing high-risk prostate cancer higher than control group.

Researchers from the University of Maryland in Baltimore conducted a case-control study to assess the association of a history of testicular cancer with later development of intermediate- to high-risk prostate cancer. Earlier studies suggested that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6%) than among men who did not have a history of testicular cancer (2.8%). Men who had testicular cancer also were more likely to develop intermediate- or high-risk prostate cancers.

The researchers analyzed Surveillance, Epidemiology, and End Results (SEER) data on 32,435 men with a history of testicular cancer and 147,044 men with a history of melanoma. Melanoma was used as the control group because there is no known association between melanoma and prostate cancer; therefore, patients with melanoma would have a similar risk for developing prostate cancer as men in the general population.

The incidence of intermediate- or high-risk prostate cancer was 5.8% in the testicular cancer group and 1.1% in the control group. Testicular cancer was associated with a 4.7 times higher risk of developing all types of prostate cancer and a 5.2 times higher risk of developing intermediate- or high-risk disease. The findings suggest that surveillance for prostate cancer needs to be considered when creating survivorship care plans for testicular cancer survivors.

The study abstract can be found at http://meetinglibrary.asco.org/content/142017-159.

Recent Videos
Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC in an interview with oncology nursing news
Anne M. Reb, PhD, NP, discussing a nurse-led intervention for fear of cancer recurrence.
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
Elizabeth Burton in an interview with Oncology Nursing News
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.